Hetero Healthcare Ltd. launches generic version of Lapatinib as ‘Hertab’ in India
Hetero Healthcare Ltd., one of the leading generic pharmaceutical companies in India and largest producer of anti-retroviral drugs in the world, has announced the launch of generic version of Lapatinib (250 mg) tablets in India. Hetero is marketing and distributing the product under the brand name ‘HERTAB’. It is made available in two stock keeping units, each comprising 30 tablets and 150 tablets. HERTAB is an oral therapy indicated for the treatment of postmenopausal women with HER2-positive advanced breast cancer patients whose disease has progressed after taking Trastuzumab therapy. Lapatinib is used along with other medication like Capecitabine or Letrozole, to inhibit the growth of cancer cells in body.
To know more about the latest update on this treatment protocol and treating centers offering the same as well as
for getting your reports reviewed, post a query
